Histological characterization of bone marrow in ectopic bone, induced by devitalized Saos-2 human osteosarcoma cells.
نویسندگان
چکیده
UNLABELLED Devitalized Saos-2, cultured human osteosarcoma cells, or guanidinium-hydrochloride (GuHCl) extracts of these cells, induce ectopic bone and marrow formation when implanted subcutaneously in Nu/Nu mice. The aim of the present study was to characterize the bone marrow induced by Saos-2 cell extracts, specifically to determine which of the four major hematopoietic cell lineages: erythropoietic, granulopoietic, lymphopoietic and megakaryocytic, are induced by Saos-2 cell derivatives. METHODS Immunohistochemical localization of specific antigens was used to determine the presence of each major cell type (glycophorin A for erythropoietic, neutrophil elastase for granulopoietic, factor-VIII related antigen for megakaryocytes, and CD79a for B lymphocytes). RESULTS Standard H & E stains confirmed the presence of normally organized apparently complete bone marrow within all newly induced bone at 3 weeks post-implantation of devitalized Saos-2 cells. Immunohistochemistry confirmed the presence of erythropoietic cells, granulopoietic cells, megakaryocytes and B lymphocytes in the ectopic marrow. CONCLUSION Saos-2 cells (freeze-dried) or their extracts, implanted subcutaneously into Nu/Nu mice, can induce normal marrow that is host-derived, and contains all major hematopoietic cell lineages. CLINICAL SIGNIFICANCE Saos-2 induced marrow could potentially restore deficient marrow and promote bone repair.
منابع مشابه
Design, Synthesis and Characterization of Nano niosomal Delivery system Containing paclitaxel drug for Drug Delivery to Osteosarcoma Cell Line (Saos-2)
Introduction: Osteosarcoma is one of the cancers that current treatment strategies using chemotherapy drugs have not been very successful due to multiple drug resistance and harmful side effects. The use of nano-niosomal systems in the delivery of paclitaxel is one of the attractive approaches to overcome these limitations. paclitaxel is a powerful anticancer agent used in the treatment of many...
متن کاملMicroRNA-214 regulates osteosarcoma survival and growth by directly targeting phosphatase and tensin homolog.
An increasing number of microRNAs (miRNAs) have been identified as diagnostic and prognostic biomarkers, as well as additional therapeutic tools, in skeletal diseases. Recent studies have established the pathophysiological role of miR‑214, using human osteoporotic bone specimens. However, miR‑214 expression levels and the underlying regulatory mechanism in human osteosarcoma remain unclear. Qua...
متن کاملCharacterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.
BACKGROUND Osteosarcomas are malignant bone tumors consisting of cells with abnormal cellular functions. Although osteosarcoma-derived cells are commonly used for osteoblastic models, the molecular composition of the osteosarcoma extracellular matrix (ECM) is not well characterized. MATERIALS AND METHODS We compared three osteosarcoma cell lines (MG-63, Saos-2 and U-2 OS) with normal human os...
متن کاملمقایسه تاثیرمواد پیوندی Totudentو Bio-oss بر روی فعالیت میتوکندری وآلکالین فسفاتازی سلولهای شبه استئوبلاست saos-2
Abstract Background: Several reports on clinical utility of various Bone Substitute Materials, (BSM) for grafting have shown successful results. The most important factor in successful grafting of BSM is the physiological and histological behavior of this material which can be evaluated by observing, rate of survival and proliferation of osteogenic cells. This research was conducted to exami...
متن کاملRelaxin promotes in vitro tumour growth, invasion and angiogenesis of human Saos-2 osteosarcoma cells by AKT/VEGF pathway.
OBJECTIVES In the present study, we determine the role of relaxin on cellular growth, invasion and angiogenesis of osteosarcoma Saos-2 cells in vitro, and discuss the molecular mechanisms of this action. MATERIALS AND METHODS Saos-2 cells were transfected with Akt1/2 siRNA or VEGF siRNA for 24 hours then treated with 10-100 ng/mL recombinant human relaxin-2 (rh-RLN) for 48 h. MTT, matrigel an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- International journal of clinical and experimental medicine
دوره 6 2 شماره
صفحات -
تاریخ انتشار 2013